



PATIENT

Fenris Wood

SPECIES

Canine

BREED

Norwegian Elkhound

SEX

Male

AGE

11 years

WEIGHT

21.8

INTERPRETED BY

Maggie Machen Lamy,
DVM, DACVIM
(Cardiology)

IMAGING PERFORMED BY

A. Westcott, DVM

HOSPITAL NAME

Alastair Westcott, DVM

REFERRING VET

Dr. Westcott

INVOICE

47712

DATE

4/28/26

PRESENTING CLINICAL SIGNS

History: Initially presented 3/14/26 for a 1-week history of persistent, nonproductive, dry hacking cough, occurring in prolonged episodes (up to 30 minutes), most notable at night and early morning. At that time: No heart murmur was auscultated. Lung sounds were normal. No cough was elicited on tracheal palpation. Thoracic and cervical radiographs were recommended but declined. A therapeutic trial of Apoquel was initiated (16 mg tablets, ½ tablet PO q12h x 2 weeks, then q24h), with cough suppressant declined. At recheck on April 20 for dental prophylaxis, the owner reported complete resolution of coughing following Apoquel treatment however, a new grade III/VI systolic murmur was auscultated at the left apex. Assess prior to dental.

-Abnormal PE/Chem/CBC/UA Results: Grade III/VI systolic murmur PMI left apex. Labs: unremarkable. ECG: normal. CXR showed no overall cardiomegaly, but a slight LA bulge noted on lateral view. Mild bronchial patterning. Normotensive.


ECHOCARDIOGRAM FINDINGS

2D, m-mode, color flow and doppler imaging is available. Diffuse thickening of mitral valve leaflets (anterior>posterior) with mild prolapse into the left atrial lumen. Moderate eccentric mitral regurgitation with moderate left atrial dilation (LA:Ao >1.6). Borderline LV diameter with adequate myocardial function. The tricuspid valve appears mildly thickened, with trace tricuspid regurgitation. Normal velocity. Normal right atrial and ventricular diameter. The pulmonic and aortic valves are normal in morphology and mobility. Normal pulmonic and aortic outflow velocities. No aortic and trace pulmonic insufficiency. No pericardial or pleural effusion noted. No cardiac tumors observed.

CARDIAC CHART

CANINE CARDIAC PARAMETERS	MR VMAX (m/s)	TR VMAX (m/s)	LA/AO (Boon method)	LA/AO (Heart Base; Swe)	FS (%)	EF (%)	EPSS (cm)
NORMAL PARAMETER	4.5-5.5	<2.7	1.3	<1.6	28-40	40-100	<0.6
PATIENT	5.0	2.0	NM	1.75	38	70	0.4
CANINE CARDIAC PARAMETERS	HR (BPM)	AV VMAX (m/s)	PV MAX (m/s)	BODY WEIGHT	LA 2D short axis Base view (cm)	LVIDd Avg; 2D and m-mode short axis (cm)	LVIDs Avg; 2D and m-mode short axis (cm)
NORMAL PARAMETER	50-100	0.7-1.7	0.7-1.6	BELOW	BELOW	BELOW	BELOW
PATIENT	NM	1.6	0.6	21.8	3.5	4.2	2.5
*Normal chamber parameters expressed as a mean value (SD)				3	1.27 (5.3)	2.46 (2.46)	1.36 (5.5)
BODY WEIGHT DEPENDENT PARAMETERS				5	1.40 (4.5)	2.74 (5.2)	1.60 (4.7)
*Note: All measurements based upon multi-modal images and methods. An average value is reported.				10	1.50 (3.8)	3.27 (3.5)	2.06 (3.1)
				15	1.83 (2.0)	3.71 (2.4)	2.43 (2.1)
				20	2.02 (1.9)	4.14 (2.2)	2.80 (2.0)
				25	2.18 (2.4)	4.48 (2.9)	3.10 (2.5)
				30	2.33 (3.3)	4.83 (3.9)	3.39 (3.4)
				35	2.48 (4.3)	5.17 (5.0)	3.69 (4.5)
				40	2.62 (5.2)	5.48 (6.1)	3.96 (5.4)
				50	2.88 (7.1)	6.07 (8.3)	4.46 (7.4)

Adapted from June Boon, Veterinary Echocardiography, 1998
Rishniw M and Hollis NE, J Vet Intern Med 2000; 14:429-435
Hansson et al, Vet Rad and Ultrasound 2002
Bonagura et al. Echocardiography: principles of interpretation, Vet Clin North Am 15:1177, 1995



PATIENT

Fenris Wood

SPECIES

Canine

BREED

Norwegian Elkhound

SEX

Male

AGE

11 years

WEIGHT

21.8

INTERPRETED BY

Maggie Machen Lamy,
DVM, DACVIM
(Cardiology)

IMAGING PERFORMED BY

A. Westcott, DVM

HOSPITAL NAME

Alastair Westcott, DVM

REFERRING VET

Dr. Westcott

INVOICE

47712

DATE

4/28/26

INTERPRETATION OF THE FINDINGS & FURTHER RECOMMENDATIONS

Chronic degenerative valve disease causing moderate mitral and trace tricuspid regurgitation. Moderate left atrial enlargement indicates there is relatively low risk for imminent complication; however, risk for progression to spontaneous congestive heart failure in the future is elevated. No additional issues such as pulmonary hypertension are identified.

Given the risk for progression and results of the EPIC trial, Pimobendan is indicated in this patient as below. Assessment of progression in the future will help predict long term outcome; however, prognosis is guarded at this stage (B2). Fifty percent of stage B2 patients typically develop CHF within 2-2.5 years of diagnosis. The median time to development of CHF in B2 cases treated with pimobendan is 3.5 years.

While mainstem bronchi compression may certainly be contributing to an increase in coughing, other primary airway contributions should also be considered (tracheal collapse, COPD/chronic bronchitis, etc.). Consider hydrocodone for any mechanical component due to cardiomegaly. If the cough is poorly controlled and/or progresses long term, pulmonary hypertension (PAH) can develop secondarily. Signs of clinically relevant PAH include exertional dyspnea or exertional syncope. It is important to note that PAH does not cause the cough; rather, the cough leads to PAH.


Omega fatty acid supplementation and mild salt restriction may also be of some long-term benefit. Monitor for development of a progressive cough, labored breathing, exercise intolerance or collapse episodes.

Once on the medication for 3-5 days, anesthetic risk is considered mildly elevated. Pre-oxygenate for 5-10 minutes prior to induction. Cardiac protective drug choices (opioid/benzodiazepine premedication, Propofol or alfaxalone induction, iso or sevo gas) are recommended. Monitor for arrhythmias, hypotension, and/or hypoxia both intra and post-operatively and intervene as necessary. Judicious IV fluid rates are recommended to avoid fluid overload. Avoid heart rate stimulating drugs such as atropine unless clinically indicated.

PLAN

Institute heart muscle support Pimobendan 0.3mg/kg PO q12h. Baseline BP recommended. Consider hydrocodone and/or further cough evaluation as indicated.

Recommend monitor for progression with a recheck echocardiogram in 6 months, sooner if any development of additional clinical signs in the interim.



PATIENT

Fenris Wood

SPECIES

Canine

BREED

Norwegian Elkhound

SEX

Male

AGE

11 years

WEIGHT

21.8

INTERPRETED BY

Maggie Machen Lamy,
DVM, DACVIM
(Cardiology)

IMAGING PERFORMED BY

A. Westcott, DVM

HOSPITAL NAME

Alastair Westcott, DVM

REFERRING VET

Dr. Westcott


INVOICE

47712

DATE

4/28/26

IMAGES



The information and recommendations provided are based on the images presented by the referring veterinarian. No evaluation can be communicated regarding pathology that was not visible in the image/video clips provided.

Thank you for this referral. This report was generated using transcription software, and minor dictation errors may be present. If the clinical or image interpretation does not parallel your findings or if I can be of any further assistance, please contact me.

Maggie Machen Lamy, DVM

Diplomate of the American College of Veterinary Internal Medicine (Cardiology)

info@sonopath.com